CRDF (Cardiff Oncology) Marketable Securities: $37.51 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRDF Cardiff Oncology Inc CRDF
44 GF Score
Price $0.88
GF Value $1.40
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Marketable Securities?

Cardiff Oncology CRDF -0.97% 44 Marketable Securities is $37.51 Mil as of Mar. 2026. GuruFocus rates CRDF with a GF Score™ of 44/100 and a GF Value™ of $1.40 (Possible Value Trap). The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Cardiff Oncology's Marketable Securities for the quarter that ended in Mar. 2026 was $37.51 Mil.

Cardiff Oncology's annual Marketable Securities declined from Dec. 2023 ($53.17 Mil) to Dec. 2024 ($40.28 Mil) but then increased from Dec. 2024 ($40.28 Mil) to Dec. 2025 ($40.83 Mil).

Cardiff Oncology  (NAS:CRDF) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Cardiff Oncology Marketable Securities Related Terms

Cardiff Oncology Marketable Securities Historical Data

* Premium members only.

The historical data trend for Cardiff Oncology's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology Marketable Securities Chart

Cardiff Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 128.88 88.92 53.17 40.28 40.83

Cardiff Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.79 60.17 50.46 40.83 37.51
CRDF
44GF Score
Cardiff Oncology Inc CRDF
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiff Oncology Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $37.51 Mil mean?
Cardiff Oncology (CRDF) has a Marketable Securities of $37.51 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Cardiff Oncology and its competitors.
Is Cardiff Oncology's Marketable Securities too high?
Cardiff Oncology's current Marketable Securities is $37.51 Mil. Overall, Cardiff Oncology has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Marketable Securities compare to MAIA and TELO?
Cardiff Oncology's Marketable Securities of $37.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Cardiff Oncology and its competitors. Cardiff Oncology's current Marketable Securities is $37.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.40, compared to a current price of $0.88 — trading 37% below its estimated fair value. The current Marketable Securities is $37.51 Mil. Cardiff Oncology's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Marketable Securities is $37.51 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cardiff Oncology (CRDF) Overvalued in 2026?

Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued. The current stock price of $0.88 is trading 37% below its estimated GF Value™ of $1.40. GuruFocus considers Cardiff Oncology to be Possible Value Trap.

Key valuation signals for CRDF:

  • Marketable Securities: $37.51 Mil
  • GF Value™: $1.40 vs. price of $0.88 (37% below fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
44GF Score

Get the complete analysis for CRDF

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.88
Price
$1.40
GF Value